BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021:S0923-7534(21)04820-1. [PMID: 34861373 DOI: 10.1016/j.annonc.2021.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hack J, Crabb S. Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.015] [Reference Citation Analysis]
2 Fournel L, Charrier T, Huriet M, Iaffaldano A, Lupo A, Damotte D, Arrondeau J, Alifano M. Prognostic impact of inflammation in malignant pleural mesothelioma: a large-scale analysis of consecutive patients. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.014] [Reference Citation Analysis]
3 Remon J, Hendriks LEL, Bironzo P. Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease. Ann Oncol 2021:S0923-7534(21)04850-X. [PMID: 34883215 DOI: 10.1016/j.annonc.2021.11.019] [Reference Citation Analysis]
4 Banna GL, Signori A, Curioni-fontecedro A, Cortellini A, Ponzano M, Giunta EF, Rebuzzi SE, Chan S, Gebbia V, van Eeden R, Addeo A, Ottensmeier C. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. European Journal of Cancer 2022;166:287-99. [DOI: 10.1016/j.ejca.2022.02.030] [Reference Citation Analysis]